Key result
Bioengineered strategies show significant clinical potential to augment cardiovascular repair.
Why the study?
Clinical trials of cell therapy have demonstrated largely neutral results, but new insights into inflammation and mechanisms of natural myocardial regeneration highlight novel bioengineered strategies.
Highlights the emerging role of inflammation and bioengineering in myocardial regeneration strategies.
Cautious trial evaluation of bioengineered cardiovascular repair is needed; leaves open questions on clinical translation and efficacy.
Cardiovascular disease remains the leading cause of death worldwide. While clinical trials of cell therapy have demonstrated largely neutral results, recent investigations into the mechanisms of natural myocardial regeneration have demonstrated promising new intersections between molecular, cellular, tissue, biomaterial, and biomechanical engineering solutions. New insight into the crucial role of inflammation in natural regenerative processes may explain why previous efforts have yielded only modest degrees of regeneration. Furthermore, the new understanding of the interdependent relationship of inflammation and myocardial regeneration have catalyzed the emergence of promising new areas of investigation at the intersection of many fields.
No takes yet. Share an insight, caveat, or question.
Elde et al. (2021) conducted a review in Cardiovascular disease / Ischemic heart disease. Bioengineered strategies (molecular, cellular, tissue, biomaterial, biomechanical) was evaluated. Bioengineered strategies, including molecular, cellular, tissue, biomaterial, and biomechanical approaches, show significant potential for clinical translation to augment cardiovascular repair.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: